The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
March 12th 2025
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.
Risk for CVD Increases Following INSTI Use for HIV
June 28th 2022A possible connection between integrase strand-transfer inhibitor (INSTI) use for HIV and cardiovascular disease (CVD) was investigated in this new study from an international team wanting more knowledge on the drug class’s treatment effects.
Read More
The Senate passed a bipartisan gun law, the first major gun legislation in nearly 30 years, which now goes to the House; HIV cases dropped during the pandemic, perhaps due to lack of testing; researchers say COVID-19 vaccines have saved nearly 20 million lives but could be even more effective.
Read More
Meningococcal Vaccine Uptake Lagging Among People Living With HIV
June 23rd 2022The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.
Read More
An experimental cancer drug made 100% of patients’ rectal tumors disappear in a small study; US military members with HIV with an undetectable viral load and no symptoms will no longer face restrictions in deployment or commission; President Biden may sign an executive order on abortion rights depending on the Supreme Court’s ruling.
Read More
DREAMS HIV Interventions Linked to Favorable Behavioral Outcomes Among Young Women in South Africa
May 19th 2022Adolescent girls and young women in South Africa were more likely to practice favorable sexual behaviors if they accessed DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe)–like interventions such as school-based HIV prevention and HIV testing.
Read More
The UK’s The Food Chain Fosters Food Engagement for PLWH Through Cooking
May 16th 2022Anna Brewster, services and volunteer manager at The Food Chain, a London-based charity that provides short-term assistance to persons living with HIV (PLWH), discusses how education provided through the Eating Positively program connects the importance of food and proper nutrition to health outcomes.
Watch
Dr Anna Marzec-Bogusławska: Advocacy Helped to Overcome Fear, Stigma of HIV/AIDS in Poland
May 9th 2022Anna Marzec-Bogusławska, MD, MPH, managing director, National AIDS Center, Warsaw, Poland, discusses how stigma and discrimination permeated the beginning of the HIV/AIDS epidemic the country in the early 1980s and ways that advocates stepped up to overcome peoples’ fears.
Watch
PLWH in Romania Need More Comprehensive Care, Advocate Says
May 3rd 2022Nicoleta Dascalu, founding member and advocacy manager of Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS), discusses the status of care for persons living with HIV/AIDS (PLWH) in Romania, including health care coverage and lack of adequate medication access.
Watch
Dr Jason Myers Discusses How New Zealand Pivoted to Continue HIV Care During the Pandemic
April 29th 2022Jason Myers, PhD, CEO of the New Zealand AIDS Foundation, addresses how New Zealand promptly adjusted its delivery of services for people living with HIV and AIDS in New Zealand, with examples including HIV self-test kits, online counseling, and provision of mental health care assistance.
Watch
TDF-Based PrEP Associated With Increased Risk of Kidney Adverse Events, Review Finds
April 27th 2022According to a review, few individuals initiating tenofovir disoproxil fumarate (TDF)–based HIV pre-exposure prophylaxis (PrEP) experienced clinically significant kidney impairment, although the risk was increased.
Read More
Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.
Read More
Protease Inhibitor–Based ART Associated With Babies Born Small or Very Small
April 6th 2022A large systematic review on pregnant women living with HIV found that protease inhibitor–based antiretroviral therapy (ART) use was associated with increased risk of babies being born small or very small for their gestational age, but not with other adverse pregnancy outcomes.
Read More
Medicare Must Address High ART Costs, Investigators Argue
April 4th 2022With more people living with HIV now reaching advanced ages and qualifying for Medicare coverage, this new study investigated HIV-related influences on their health care spending, particularly antiretroviral therapy (ART), compared with a population who does not have HIV.
Read More
Dr Jorge Plutzky Explains How Traditional CV Risk Prediction Models Fall Short for Patients With HIV
March 30th 2022Traditional cardiovascular (CV) risk prediction models may not apply accurately to patients with HIV who may develop the cardiovascular disease younger than usual, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Watch